ATE290880T1 - Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält - Google Patents

Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Info

Publication number
ATE290880T1
ATE290880T1 AT01936440T AT01936440T ATE290880T1 AT E290880 T1 ATE290880 T1 AT E290880T1 AT 01936440 T AT01936440 T AT 01936440T AT 01936440 T AT01936440 T AT 01936440T AT E290880 T1 ATE290880 T1 AT E290880T1
Authority
AT
Austria
Prior art keywords
inosine
cytosine
composition containing
polycationic peptide
antigen composition
Prior art date
Application number
AT01936440T
Other languages
English (en)
Inventor
Alena Egyed
Karen Lingnau
Frank Mattner
Michael Buschle
Walter Schmidt
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of ATE290880T1 publication Critical patent/ATE290880T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/18Type of nucleic acid acting by a non-sequence specific mechanism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01936440T 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält ATE290880T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
PCT/EP2001/006437 WO2001093903A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine

Publications (1)

Publication Number Publication Date
ATE290880T1 true ATE290880T1 (de) 2005-04-15

Family

ID=3683921

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung

Country Status (7)

Country Link
US (2) US7148191B2 (de)
EP (1) EP1286695B1 (de)
AT (2) AT410173B (de)
AU (1) AU2001262345A1 (de)
DE (1) DE60109443T2 (de)
WO (1) WO2001093903A1 (de)
ZA (1) ZA200209479B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520200A (en) * 1999-12-22 2004-04-30 Aventis Pasteur Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product
DE60100814T2 (de) 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AU2001297693A1 (en) * 2000-12-08 2002-09-12 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
CA2433561C (en) * 2001-01-03 2014-04-01 Willmar Poultry Company, Inc. Compositions including gram negative siderophore receptor proteins and methods of use
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
JP2004519453A (ja) * 2001-01-05 2004-07-02 インターツェル・アクチェンゲゼルシャフト ポリカチオン性化合物の用途
WO2003047602A1 (en) * 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20050221381A1 (en) * 2002-02-28 2005-10-06 Christof Klade Method for isolating ligands
US20060057104A1 (en) * 2002-04-24 2006-03-16 The Regents Of The University Of California Office Of The President Methods for stimulating tlr irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses
US7439349B2 (en) * 2002-07-03 2008-10-21 Andres Salazar Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof
WO2004011650A2 (en) * 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004024182A2 (en) * 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2314604A3 (de) 2002-10-15 2011-05-25 Intercell AG Bindungdsfaktoren von Gruppe B-Streptococcus, dafür kodierende Nukleinsäuren und Verwendungen davon
WO2004055041A2 (en) * 2002-12-13 2004-07-01 Case Western Reserve University Defensin-inducing peptides from fusobacterium
EP2287314A1 (de) 2003-03-04 2011-02-23 Intercell AG Streptococcus-pyogenes-Antigene
US7704514B2 (en) 2003-03-24 2010-04-27 Intercell Ag Vaccines
CN101214375B (zh) * 2003-03-24 2011-04-06 英特塞尔股份公司 改进的疫苗
ATE449177T1 (de) 2003-03-31 2009-12-15 Intercell Ag Staphylococcus epidermidis antigene
JP2007525157A (ja) 2003-04-15 2007-09-06 インターツェル・アクチェンゲゼルシャフト 肺炎連鎖球菌抗原
CN101864431A (zh) 2003-05-07 2010-10-20 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
WO2004106367A2 (en) 2003-05-30 2004-12-09 Intercell Ag Enterococcus antigens
EP1678316B1 (de) * 2003-09-19 2011-08-17 Epitopix, LLC Campylobacter-polypeptide und verwendungsverfahren
US20090060875A1 (en) * 2004-10-29 2009-03-05 Intercell Ag HCV Vaccines for Chronic HCV Patients
NZ560612A (en) * 2005-02-14 2011-01-28 Epitopix Llc Polypeptides from staphylococcus aureus and methods of use
AU2007264205B2 (en) 2006-06-28 2013-04-18 Statens Serum Institut Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
US8529911B2 (en) 2006-07-07 2013-09-10 Intercell Austria Ag Small Streptococcus pyogenes antigens and their use
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
EP2269624A3 (de) 2007-01-12 2012-08-08 Intercell AG Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür
MX2009009530A (es) * 2007-03-07 2010-05-19 Nventa Biopharmaceuticals Corp Composiciones de acidos nucleicos cerrados bicatenarios.
EP2152731A2 (de) * 2007-05-02 2010-02-17 Intercell AG Klebsiella-antigene
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
AU2008265218A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20110038888A1 (en) * 2008-01-10 2011-02-17 Peter Emtage Adjuvant compositions comprising poly-ic and a cationic polymer
EP2265634A2 (de) 2008-03-17 2010-12-29 Intercell AG Peptide schutzmittel gegen s. pneumoniae und zusammensetzungen, verfahren und anwendung im zusammenhang damit
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
CN102076358B (zh) 2008-06-27 2016-08-17 硕腾有限责任公司 新颖的佐剂组合物
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
EP2411046B1 (de) 2009-03-23 2017-12-06 Epitopix, LLC Polypeptide und immunisierungszusammensetzungen mit gram-prositiven polypeptiden und anwendungsverfahren
EP2319871A1 (de) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
WO2011042548A1 (en) 2009-10-09 2011-04-14 Sanofi-Aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2308896A1 (de) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
WO2012031760A1 (en) 2010-09-08 2012-03-15 Medigene Ag Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
RU2730011C2 (ru) 2013-09-19 2020-08-14 Зоэтис Сервисиз Ллс Адъюванты на масляной основе
FI3244920T3 (fi) 2015-01-16 2023-08-04 Zoetis Services Llc Suu- ja sorkkatautirokote
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
WO2019158636A1 (en) 2018-02-16 2019-08-22 2A Pharma Ab Parvovirus structural protein for the treatment of autoimmune diseases
EP3527223A1 (de) 2018-02-16 2019-08-21 2A Pharma AB Mutiertes parvovirus-strukturprotein
CN114127101A (zh) 2019-05-20 2022-03-01 瓦尔尼瓦公司 用于治疗或预防呼吸道感染的亚单位疫苗
US12214028B2 (en) 2019-05-31 2025-02-04 Universidad De Chile Immunogenic formulation that induces protection against shiga toxin-producing Escherichia coli (STEC)
EP4058056A1 (de) 2020-10-07 2022-09-21 Valneva Sweden AB Cholera-impfstoffformulierung
EP4319804A2 (de) 2021-04-09 2024-02-14 Valneva SE Impfstoff gegen humanes metapneumovirus
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
US20250213667A1 (en) 2022-06-01 2025-07-03 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6801650D0 (pt) 1968-08-20 1973-03-07 R Maes Processo para preparacao de complexos geradores de interferon
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
AU3891097A (en) 1996-07-24 1998-02-10 Michelle M. Hanna Base-protected nucleotide analogs with protected thiol groups
EP1272215B1 (de) * 2000-04-14 2007-10-10 Intercell AG Modifizierte peptide enthaltende pharmazeutische präparationen
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung

Also Published As

Publication number Publication date
DE60109443T2 (de) 2006-04-13
ZA200209479B (en) 2003-11-21
WO2001093903A1 (en) 2001-12-13
AU2001262345A1 (en) 2001-12-17
EP1286695A1 (de) 2003-03-05
US20070218073A1 (en) 2007-09-20
US7148191B2 (en) 2006-12-12
US20030162738A1 (en) 2003-08-28
AT410173B (de) 2003-02-25
DE60109443D1 (de) 2005-04-21
ATA10002000A (de) 2002-07-15
EP1286695B1 (de) 2005-03-16

Similar Documents

Publication Publication Date Title
ATE290880T1 (de) Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE500323T1 (de) Subtilisin-variante
BG101103A (bg) Теломераза при бозайници
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
AR038568A1 (es) Anticuerpos anti-a beta y su uso
ATE380822T1 (de) Funf-helix protein
SE0002102D0 (sv) Chemical compound
CL2009000575A1 (es) Anticuerpos aislados anti-interleuquina 12 (anti il-12) de mamiferos, secuencia de nucleotidos, vector, celula y metodo de produccion, composicion y dispositivo medico que contienen, util en el diagnostico y tratamiento de condicones relacionadas con il-12.
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
ATE247484T1 (de) Von der telomerase abgeleitete antigene peptide
BR0114646A (pt) anticorpos anti-lt-beta-r humanizados
DE69824013D1 (de) Impfstoff gegen hpv
TR199900267T2 (xx) GnRH-L�kotoksin kimeralar�.
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
DE60129572D1 (de) Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
EA200600738A1 (ru) Способ
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
DE69938725D1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
ATE321853T1 (de) Humanische pellino-polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1286695

Country of ref document: EP